Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals is a clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers. Its lead candidates include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an anti-metabolite for acute myeloid leukemia treatment.
Overview
Strengths
- Analysts expect revenues to grow in the coming year.
- The company has high returns. ROIC (100.00%) is higher than the sector mean (6.02%).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 100.0% |
| Net Debt/EBITDA | 100.0 |